Puik Jisce R, Meijer Laura L, Le Large Tessa Ys, Prado Mireia Mato, Frampton Adam E, Kazemier Geert, Giovannetti Elisa
Department of Surgery, VU University Medical Center, Amsterdam, The Netherlands.
Department of Medical Oncology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands.
Pharmacogenomics. 2017 Sep;18(14):1343-1358. doi: 10.2217/pgs-2017-0010. Epub 2017 Aug 23.
Cholangiocarcinoma (CCA) is a lethal malignancy originating from the biliary tract epithelium. Most patients are diagnosed at an advanced stage. Even after resection with curative intent, prognosis remains poor. Previous studies have reported the evolving role of miRNAs as novel biomarkers in cancer diagnosis, prognostication and chemotherapy response. Various miRNAs, such as miR-21, miR-26, miR-122 and miR-150, have been identified as possible blood-based biomarkers for noninvasive diagnosis of CCA. Moreover, epithelial-mesenchymal transition (EMT)- and angiogenesis-associated miRNAs have been implicated in tumor cell dissemination and are able to determine clinical outcome. In fact, miRNAs involved in cell survival might even determine chemotherapy response. This review provides an overview of known miRNAs as CCA-specific biomarkers.
胆管癌(CCA)是一种起源于胆道上皮的致命性恶性肿瘤。大多数患者在晚期才被诊断出来。即使进行了根治性切除,预后仍然很差。先前的研究报道了微小RNA(miRNA)作为癌症诊断、预后和化疗反应的新型生物标志物的不断演变的作用。各种miRNA,如miR-21、miR-26、miR-122和miR-150,已被确定为可能用于CCA无创诊断的血液生物标志物。此外,上皮-间质转化(EMT)和血管生成相关的miRNA与肿瘤细胞扩散有关,并能够决定临床结果。事实上,参与细胞存活的miRNA甚至可能决定化疗反应。本综述概述了已知的作为CCA特异性生物标志物的miRNA。